Concord Biotech has successfully completed regulatory inspections at its Unit-II Formulation Facility, conducted by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda. The inspection took place from June 18, 2026 to June 24, 2026, and was concluded successfully.
The successful completion of PPB and NDA inspection marks a significant step in the company’s global growth journey. This achievement reinforces its commitment to the highest standards of quality and regulatory excellence while strengthening its global manufacturing and regulatory footprint.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
